New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:21 EDTCELGCelgene still has upper hand in patent case, says Wells Fargo
After a federal court issued its Markman opinion in the patent case between Celgene and Natco, Wells Fargo believes that Natco will have a difficult time circumventing Celgene's patents, and the firm does not believe that Natco can win a complete victory. However, the firm thinks that Natco may not settle immediately, and it expects intellectual property issues to remain an overhang on Celgene's stock. Still, the firm finds Celgene's valuation attractive and recommends buying the shares.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
13:21 EDTCELGAlphabet, Celgene, others could rise 20% over next year, Barron's says
Subscribe for More Information
November 20, 2015
10:52 EDTCELGFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 17, 2015
08:22 EDTCELGSignificant Celgene overhang removed, says JMP Securities
Subscribe for More Information
November 16, 2015
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use